https://www.selleckchem.com/pr....oducts/motolimod-vtx
ms of operative time, blood loss and LOS without differences in major complications and R0 resection rate. Surgical society guidelineshave recommendedchangingthe treatment strategy for early esophageal cancer during the novel coronavirus (COVID-19) pandemic. Delaying resection canallow for interimdisease progression, but the impact of this delay on mortality is unknown. The COVID-19 infection rate at which immediate operative risk exceeds benefit is unknown. We sought to model immediate versus delayed surgical resection in a
Like
Comment
Share
